Skip to content

瓦雷克斯影像

US · VREX #3431 按市值排名
18.41 -0.06 -0.32%
实时 - 追踪5344个代码 - 心跳于101秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 1.58 高于历史水平 第70百分位
5年平均 1.34 · 在Medical Devices中排名第43/125
市盈率 34.79 高于历史水平 第86百分位
5年平均 14.57 · 前瞻 22.50 · 在Medical Devices中排名第30/38
市销率 0.91 处于历史正常水平 第65百分位
5年平均 0.81 · 前瞻 0.88 · 在Medical Devices中排名第24/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
瓦雷克斯影像 (VREX) 781.75M 34.74 1.57 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值21.39 经济护城河None 不确定性High

当前股价低于晨星合理价值估算16.2%。

合理价值

Varex Imaging Corp receives a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 14% discount to our quantitative fair value estimate of $21.39 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to market value ratio of 1.4, which ranks in the top 30% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be undervalued.

The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's sales yield of 110.8%, for example, falls in the top 40% compared with global peers. This company has a robust ability to generate sales without much capital investment, freeing up more capital to be returned to shareholders in the long run. This characteristic further promotes our favorable price/fair value ratio.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

瓦雷克斯影像 讨论区 0 条评论

发表评论